ArticleCureus2025
Acute Macular Neuroretinopathy Following COVID-19 Infection: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 24-year-old female presented with a new scotoma in her left eye one week after testing positive for COVID-19. Fundoscopy revealed an inferonasal perifoveal retinal pigment epithelial (RPE) lesion in the left eye. Optical coherence tomography (OCT) displayed an area of outer retinal defect involving the photoreceptor layer with ellipsoid zone disruption. OCT angiography (OCTA) showed decreased reflectivity in the deep capillary plexus of the affected area. The patient was diagnosed with acute macular neuroretinopathy (AMN) and monitored without treatment. At a one-month follow-up, minimal improvement in the scotoma was noted, with OCT showing mild improvement. At four months, the scotoma remained stable, with a persistent outer retinal defect on OCT. Despite the persistent scotoma and outer retinal defect, the patient maintained good central vision. Clinicians should be aware of potential ocular complications of COVID-19, including AMN, and monitor patients accordingly. Currently, there is no evidence-based treatment for AMN, and long-term follow-up studies are needed to better understand the prognosis and potential treatments for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.